Taysha gene therapies reports third quarter 2023 financial results and provides corporate and clinical updates

Data from first adult patient in reveal phase 1/2 trial showed tsha-102 was well-tolerated with no treatment-emergent saes as of 20-week assessment with sustained improvement across key efficacy measures and new improvement in r-mba, pgi-i and hand function, a hallmark characteristic of rett syndrome at week 12
TSHA Ratings Summary
TSHA Quant Ranking